Sani nudge has developed a hand hygiene tool that prompts medical professionals to clean their hands more often. Courtesy of TMC

Sani nudge, a graduate of the TMCx healthcare accelerator's nineth cohort at Houston's Texas Medical Center, is getting a significant nudge from a new collaboration with a social-impact organization based in California.

Among more than 1,000 startups that were considered, Copenhagen, Denmark-based Sani nudge was chosen as one of nine participants in the Mistletoe Research Fellowship Startup Collaboration Program, sponsored by the Mistletoe Foundation. Three dozen researchers from seven universities also are taking part in the program.

Fresh off a $1.2 million funding round, Sani nudge's technology is an automated monitoring system aimed at helping healthcare workers bolster hygiene compliance and processes through insights from data and a feature that "nudges" healthcare workers to practice proper hand hygiene. Sani nudge created the technology in conjunction with Bispebjerg Hospital and Aarhus University Hospital, both in Denmark.

In the Mistletoe program, representatives of Sani nudge will work alongside four American researchers to improve the startup's technology, thereby providing hospitals with better data and tapping the researchers' expertise in engineering and robotics to come up with related healthcare platforms. Sani nudge employs 13 people in the U.S., Denmark, and Poland.

During tests in healthcare settings, the use of Sani nudge has resulted in a jump in hand hygiene compliance of as much as 200 percent and a reduction in infections of at least 29 percent, the company says. Several hospitals in Scandinavia are using the Sani nudge system.

Theis Jensen, CEO of Sani nudge, and Dr. Marco Bo Hansen, the chief customer officer, became acquainted with Mistletoe when they met Mark Castleman — a partner at the Mistletoe Inc. global-impact investment fund — during a startup and innovation tour of Texas organized by Capital Factory, a startup accelerator with locations in Houston, Austin, and Dallas.

The three men soon found common ground in a shared vision for reducing hospital-acquired infections and combating resistance to antibiotics. Both are costly, potentially fatal problems.

At any given time, 1 in 25 patients in the U.S. are fighting hospital-acquired infections, the U.S. Department of Health and Human Services says. "These infections lead to the loss of tens of thousands of lives," according to the department, "and cost the U.S. healthcare system billions of dollars each year."

Meanwhile, more than 2 million people in the U.S. are infected each year with antibiotic-resistant bacteria, and at least 23,000 people die as a result, according to the U.S. Centers for Disease Control and Prevention (CDC).

Sani nudge's participation in the Mistletoe program kicked off July 31 and August 1 at a workshop in Tokyo. For the next nine months, the Sani nudge group — led by Rebekah Alexander, the startup's in-house data expert — will team up with its four assigned researchers to advance the startup's wireless technology.

The researchers "will work with us over the following academic year to help us take the Sani nudge solution to the next level and enable hospitals to get even more detailed hand hygiene information that can eliminate hospital-acquired infections," Sani nudge wrote on its blog.

In June 2020, the next-level Sani nudge technology is scheduled to be presented to potential investors and academic researchers in Silicon Valley. Sani nudge says Mistletoe effort will strengthen its ties to the U.S. market and the academic research community.

"There are many opportunities within healthcare IoT that can help both patients and hospitals, and our system is designed to embrace these opportunities," Hansen says.

Hansen, a physician, says he'll be vigilantly advocating that his Sani nudge colleagues and the Mistletoe researchers keep hospital patients and staff in mind as Sani nudge moves forward with its innovations.

"We have to make sure that our solutions always generate value to the end users and can easily be used by the clinicians, infection preventionists, and hospital managers," he says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Biosciences startup becomes Texas' first decacorn after latest funding

A Dallas-based biosciences startup whose backers include millionaire investors from Austin and Dallas has reached decacorn status — a valuation of at least $10 billion — after hauling in a series C funding round of $200 million, the company announced this month. Colossal Biosciences is reportedly the first Texas startup to rise to the decacorn level.

Colossal, which specializes in genetic engineering technology designed to bring back or protect various species, received the $200 million from TWG Global, an investment conglomerate led by billionaire investors Mark Walter and Thomas Tull. Walter is part owner of Major League Baseball’s Los Angeles Dodgers, and Tull is part owner of the NFL’s Pittsburgh Steelers.

Among the projects Colossal is tackling is the resurrection of three extinct animals — the dodo bird, Tasmanian tiger and woolly mammoth — through the use of DNA and genomics.

The latest round of funding values Colossal at $10.2 billion. Since launching in 2021, the startup has raised $435 million in venture capital.

In addition to Walter and Tull, Colossal’s investors include prominent video game developer Richard Garriott of Austin and private equity veteran Victor Vescov of Dallas. The two millionaires are known for their exploits as undersea explorers and tourist astronauts.

Aside from Colossal’s ties to Dallas and Austin, the startup has a Houston connection.

The company teamed up with Baylor College of Medicine researcher Paul Ling to develop a vaccine for elephant endotheliotropic herpesvirus (EEHV), the deadliest disease among young elephants. In partnership with the Houston Zoo, Ling’s lab at the Baylor College of Medicine has set up a research program that focuses on diagnosing and treating EEHV, and on coming up with a vaccine to protect elephants against the disease. Ling and the BCMe are members of the North American EEHV Advisory Group.

Colossal operates research labs Dallas, Boston and Melbourne, Australia.

“Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” Walter, CEO of TWG Globa, said in a news release. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”

Well-known genetics researcher George Church, co-founder of Colossal, calls the startup “a revolutionary genetics company making science fiction into science fact.”

“We are creating the technology to build de-extinction science and scale conservation biology,” he added, “particularly for endangered and at-risk species.”

Houston investment firm names tech exec as new partner

new hire

Houston tech executive Robert Kester has joined Houston-based Veriten, an energy-focused research, investment and strategy firm, as technology and innovation partner.

Kester most recently served as chief technology officer for emissions solutions at Honeywell Process Solutions, where he worked for five years. Honeywell International acquired Houston-based oil and gas technology company Rebellion Photonics, where Kester was co-founder and CEO, in 2019.

Honeywell Process Solutions shares offices in Houston with the global headquarters of Honeywell Performance Materials and Technologies. Honeywell, a Fortune 100 conglomerate, employs more than 850 people in Houston.

“We are thrilled to welcome Robert to the Veriten team,” founder and CEO Maynard Holt said in a statement, “and are confident that his technical expertise and skills will make a big contribution to Veriten’s partner and investor community. He will [oversee] every aspect of what we do, with the use case for AI in energy high on the 2025 priority list.”

Kester earned a doctoral degree in bioengineering from Rice University, a master’s degree in optical sciences from the University of Arizona and a bachelor’s degree in laser optical engineering technology from the Oregon Institute of Technology. He holds 25 patents and has more than 25 patents pending.

Veriten celebrated its third anniversary on January 10, the day that the hiring of Kester was announced. The startup launched with seven employees.

“With the addition of Dr. Kester, we are a 26-person team and are as enthusiastic as ever about improving the energy dialogue and researching the future paths for energy,” Holt added.

Kester spoke on the Houston Innovators Podcast in 2021. Listen here

.